Sugi Predict

Sugi Predict / Compounds / SCHEMBL1811862

SCHEMBL1811862

SCHEMBL1811862

NC(=O)Cc1csc(SCC(=O)NC[C@H]2CN(Cc3cccc(F)c3)CCO2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.49
▸ CCR3 P51677 2/20 0.40
▸ CCR1 P32246 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ SIGMAR1 Q99720 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ ADRA2B P18089 1/20 0.38
▸ HTR2C P28335 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1811858 1.00 ALDH1A1 (0.49) ALDH1A1CCR3CCR1SMN1; SMN2MEN1
SCHEMBL1805873 0.93 ALDH1A1 (0.51) ALDH1A1CCR3CCR1SMN1; SMN2MEN1
SCHEMBL1805878 0.93 ALDH1A1 (0.51) ALDH1A1CCR3CCR1SMN1; SMN2MEN1
SCHEMBL12625677 0.92 ALDH1A1 (0.45) ALDH1A1CCR3SMN1; SMN2MEN1KMT2A
SCHEMBL1810446 0.91 ALDH1A1 (0.51) ALDH1A1CCR3CCR1SMN1; SMN2MEN1
SCHEMBL1810450 0.91 ALDH1A1 (0.51) ALDH1A1CCR3CCR1SMN1; SMN2MEN1
SCHEMBL1811480 0.91 ALDH1A1 (0.49) ALDH1A1CCR3CCR1SMN1; SMN2MEN1
SCHEMBL1811470 0.91 ALDH1A1 (0.49) ALDH1A1CCR3CCR1SMN1; SMN2MEN1
SCHEMBL1807785 0.90 ALDH1A1 (0.46) ALDH1A1CCR3CCR1SMN1; SMN2MEN1
SCHEMBL1807781 0.90 ALDH1A1 (0.46) ALDH1A1CCR3CCR1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801108-B9 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2013-11-20 — — EP disclosed
EP-1801108-B1 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2012-11-14 — — EP disclosed
EP-1801108-B1 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2012-11-14 — — EP disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 — — US disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 — — US disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 — — US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 — — US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 — — US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 — — US disclosed
EP-1801108-A1 MORPHOLINE COMPOUND Mitsubishi Pharma Corporation (JP) 2007-06-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265257-A1 Morpholine Compound CCR3, CCR1, CCR4 ALDH1A1 2661/4885CCR3 1/4885CCR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.